Interestingly, mutations in NRAS and other MAPK signaling effector genes were enriched in nonresponsive AML patients (Amatangelo et al., 2017), indicating that the mutational profile of these genes should also be evaluated prior treatment indication in addition to IDH2 mutations. Here, IDH2 is linked to acute myeloid leukemia.